Oxeia Biopharmaceuticals, Inc. (OXEA)

Oxeia Biopharmaceuticals was planning to go public, but the IPO has been withdrawn.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -1.97M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About OXEA

Oxeia Biopharmaceuticals is a clinical-stage biotech company developing new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging. Our first two indications are for (i) mild traumatic brain injury, known as concussion, and (ii) the cognitive decline, lethargy and “brain-fog” associated with Covid-19 infection, known as Covid Longhauler syndrome (“Long Covid”). On May 1, 2017, we acquired certain rights to a ghrelin molecule OXE103 that was originally developed by Daiichi Sankyo f... [Read more]

Industry Health Care
Sector Biotechnology
Founded 2014
Employees 2
Stock Exchange NASDAQ
Ticker Symbol OXEA
Full Company Profile

Financial Performance

Financial Statements


Oxeia Biopharmaceuticals IPO Registration Document (S-1)

Oxeia Biopharmaceuticals has filed to go public with an IPO on the NASDAQ.

1 year ago - SEC